68Ga-DOTA-JR11

DRUG2 trials

Sponsors

Memorial Sloan Kettering Cancer Center, Peking Union Medical College Hospital

Conditions

Neuroendocrine TumorsTumor-Induced Osteomalacia

Phase 1

Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO

Peking Union Medical College HospitalTumor-Induced Osteomalacia

Start: 2020-03-15End: 2022-03-15Target: 50Updated: 2021-01-05

Unknown Phase

Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

CompletedNCT02609737

Memorial Sloan Kettering Cancer CenterNeuroendocrine Tumors

Start: 2015-11-13End: 2020-12-10Updated: 2022-02-01

Related Papers

Head-to-Head Comparison of <sup>68</sup>Ga-DOTA-TATE and <sup>68</sup>Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study.

2022-02-2412 citations

Theranostic trial of well differentiated neuroendocrine tumors (NETs) with somatostatin antagonists <sup>68</sup>Ga-OPS202 and <sup>177</sup>Lu-OPS201.

Journal of Clinical Oncology2017-05-209 citations